Before Site Activation: Identify Protocol Screening Challenges Before They Reach Your Clinical Research Sites

Healthcare professionals reviewing clinical trial protocol information on a laptop, with a nurse explaining screening details to a senior doctor in a modern medical setting.

By the time a clinical research site identifies a major screening bottleneck, site coordinators may have already spent hours evaluating patients who don’t meet the protocol. Screen failures pile up, the enrollment timeline starts to slip and patient recruitment costs climb. By then, the budget, the timeline and the clinical site network are already committed.

Some of these screening challenges can be identified before clinical research sites begin patient recruitment. A protocol with restrictive criteria often shows early signals in patient responses.

‍

What site burden looks like in feasibility results

Antidote’s feasibility tests are short online surveys that put a study’s draft screening questions in front of people from the target patient population before patient recruitment begins. The results point to where screening challenges may appear.

Signal in a feasibility test What it means for clinical research sites
Interest is high, but few respondents qualify Low preliminary qualification may require additional pre-screening, targeted sourcing or adjustments to recruitment projections
One criterion removes a large share of respondents That criterion needs a clear decision on where it gets checked
Respondents can’t confirm subtype, test values or dates Sites will confirm details patients couldn’t answer
A narrow treatment or device history is required The study may need more targeted patient sourcing rather than simply increasing advertising volume

‍

Four protocol patterns from Antidote’s feasibility tests

Feasibility test Criterion What the test showed What the sponsor could decide
Sleep apnea device study Body mass index (BMI) of 32 or lower 36.8% of respondents were excluded by BMI alone Whether BMI should be checked earlier in pre-screening, or whether the eligibility threshold warrants clinical review
Parkinson’s disease study Use of a specific medication delivery device in the past four months Only 4.2% reported recent device use Whether to revise the lookback window, broaden eligible device types or plan specialized sourcing
Heart failure with preserved ejection fraction (HFpEF) study Specific subtype and a clinical threshold 59.2% reported the umbrella diagnosis, and only 44.4% met the threshold Which criteria to rely on self-report for, and which need clinical confirmation
Obesity medication-switch study Stable dose over a set period, with documented weight loss Only 3.1% of respondents qualified Whether to test alternative dose stability windows or plan for higher-volume screening

In each case, feasibility testing gave the sponsor an opportunity to evaluate potential recruitment barriers before clinical research sites began screening.

‍

Interested patients make the problem easy to miss

Low enrollment is often read as low interest. Antidote’s feasibility tests show that’s not always the case. In the Parkinson’s disease test, only 9 of 214 respondents met the initial criteria, and 6 of those 9 said they were very interested in taking part.

The findings suggest that patient interest alone wasn’t the main limitation. The device-history requirement significantly reduced the number of respondents meeting the initial criteria. Without early testing, a constraint like this may only surface once clinical research sites start screening, when the cause is harder to see.

‍

How can sponsors identify screening challenges before site activation?

Sponsors can identify potential screening challenges by running the draft screener with the target patient population before patient recruitment begins. The results show which criteria remove the most respondents, which ones patients can’t confirm on their own and whether low numbers reflect weak interest or narrow criteria. Five steps make the findings useful.

Run the draft screener with the target population.

Use the protocol’s inclusion and exclusion criteria, written in patient-friendly language, so the results reflect how the target patient population responds.

Find the criterion that removes the most respondents.

One requirement often accounts for most disqualifications. That is the criterion to discuss first with the study team.

Quantify the trade-off.

Estimate how changing one requirement, such as a lookback window or a dose stability period, would change the qualified pool and the level of interest.

Decide where each criterion gets checked.

Keep criteria patients answer reliably in the online screener. For criteria patients may not answer reliably, plan an appropriate confirmation step, such as a follow-up call or a medical record review where authorized, and leave test values and imaging to the clinical research site.

Share the findings with clinical research sites before activation.

Tell site coordinators which criteria may need confirmation and what screening effort to plan for, so staffing and timelines reflect the protocol they will actually run.

‍

What to measure

Metric What it tells you
Share disqualified by each criterion Which requirement limits the qualified pool most
Preliminary qualified rate The proportion of respondents meeting initial criteria and the potential volume of preliminary matches available for referral
Very interested among qualified respondents Whether respondents who meet initial criteria want to take part
Willingness to attend clinic visits Whether respondents who meet initial criteria expect to manage the study’s visit schedule
Wants contact if the study enrolls locally Whether respondents who meet initial criteria express interest in further study contact

‍

Frequently Asked Questions

What is site burden in clinical trial recruitment?

Site burden is the extra work clinical research sites take on to enroll each patient, such as screening patients who won’t qualify, confirming details patients couldn’t provide and following up on referrals that go nowhere.

Does a feasibility test replace site feasibility assessments?

No. A patient-facing feasibility test does not replace protocol feasibility or site selection. It reduces uncertainty about how patients will respond to the protocol and where it creates friction.

When should a sponsor run a feasibility test?

Before the protocol is finalized, when criteria can still change, or before site activation, when recruitment timelines and budgets are being set.

‍

Flag screening challenges before clinical research sites absorb them

Antidote runs short feasibility tests that put protocol-based screening questions and draft patient-facing messages in front of relevant patient populations before patient recruitment begins. Sponsors see:

  • Which criteria screen out the most respondents
  • Whether low yield reflects weak interest or narrow criteria
  • How interested respondents who meet initial criteria are
  • Where additional screening support may be needed, so recruitment plans and site expectations are aligned before activation

‍

Talk to Antidote About Your Protocol
Contact With Us
On
November 20, 2026